Literature DB >> 30944993

Prognostic association of demographic and clinical factors with the change rates of symptoms and depression among patients with hepatocellular carcinoma.

Jyh-Jou Chen1, Sheng-Shiung Huang2, In-Fun Li3,4, Kuan-Pin Lin5, Shiow-Luan Tsay6.   

Abstract

PURPOSE: To identify the predictive value of demographic and clinical factors for determining changes in physical and depressive symptom among hepatocellular carcinoma (HCC) patients over time.
METHODS: We performed a prospective cohort study of 128 patients newly diagnosed with HCC in Taiwan. Each patient had four time-point data after the follow-up. Patients' physical symptoms were evaluated with the Edmonton Symptom Assessment System (ESAS). Psychological symptoms were evaluated with the Hospital Anxiety and Depression Scale (HADS). Clinical factors and demographic characteristics were predictors of physical and psychological symptoms, as estimated by a generalized estimating equation (GEE).
RESULTS: We found that patients who had a smoking habit and Barcelona Clinic Liver Cancer (BCLC) Stage B disease underwent radiofrequency ablation therapy (RFA) or liver resection, and those who had higher alanine aminotransferase (GPT) level reported more symptoms from baseline to 1 month. Symptoms increased from baseline to 3 months in elderly patients and patients with higher GPT levels. Additionally, patients who had jobs, underwent liver resection, and had BCLC Stage C disease had increased symptoms of depression from baseline to 1 month; in particular, BCLC Stage D disease had negative long-term effects on depression scores from baseline to four-time points following therapy.
CONCLUSION: Advanced BCLC stage and undergoing RFA or liver resection were most closely associated with worsening physical and psychological symptoms over time. Clinical professionals should pay attention to these factors that affect physical and psychological symptoms during treatment.

Entities:  

Keywords:  Depression; Hepatocellular carcinoma (HCC); Symptom; Symptom management theory (SMT)

Year:  2019        PMID: 30944993     DOI: 10.1007/s00520-019-04776-3

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  41 in total

Review 1.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; María Reig; Jordi Bruix
Journal:  Lancet       Date:  2018-01-05       Impact factor: 79.321

Review 2.  Hepatocellular carcinoma review: current treatment, and evidence-based medicine.

Authors:  Ali Raza; Gagan K Sood
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

3.  Longitudinal Changes in Depression Symptoms and Survival Among Patients With Lung Cancer: A National Cohort Assessment.

Authors:  Donald R Sullivan; Christopher W Forsberg; Linda Ganzini; David H Au; Michael K Gould; Dawn Provenzale; Christopher G Slatore
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

4.  Fatigue experiences in hepatocellular carcinoma patients during six weeks of stereotactic radiotherapy.

Authors:  Yeur-Hur Lai; Shiow-Ching Shun; Ya-Li Hsiao; Jeng-Fong Chiou; Lin-Lin Wei; Jo-Ting Tsai; Chung-Yu Kao
Journal:  Oncologist       Date:  2007-02

5.  Epidemiology of hepatocellular carcinoma in Japan.

Authors:  Takeji Umemura; Tetsuya Ichijo; Kaname Yoshizawa; Eiji Tanaka; Kendo Kiyosawa
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

Review 6.  Liver transplantation for hepatocellular carcinoma.

Authors:  Jerome Byam; John Renz; J Michael Millis
Journal:  Hepatobiliary Surg Nutr       Date:  2013-02       Impact factor: 7.293

7.  Depressive symptoms after treatment in hepatocellular carcinoma survivors: prevalence, determinants, and impact on health-related quality of life.

Authors:  Naoko Mikoshiba; Mitsunori Miyashita; Tomoko Sakai; Ryosuke Tateishi; Kazuhiko Koike
Journal:  Psychooncology       Date:  2013-05-19       Impact factor: 3.894

8.  Four weeks of daily assessments of anxiety, depression and activity compared to a point assessment with the Hospital Anxiety and Depression Scale.

Authors:  Cecilia Arving; Bengt Glimelius; Yvonne Brandberg
Journal:  Qual Life Res       Date:  2007-11-17       Impact factor: 4.147

9.  Symptom Distress in Patients With Hepatocellular Carcinoma Toward the End of Life.

Authors:  Lissi Hansen; Nathan F Dieckmann; Kenneth J Kolbeck; Willscott E Naugler; Michael F Chang
Journal:  Oncol Nurs Forum       Date:  2017-11-01       Impact factor: 2.172

10.  Bridging therapy effectiveness in the treatment of hepatocellular carcinoma prior to orthotopic liver transplantation.

Authors:  Maria M Rubinstein; Andreas Kaubisch; Milan Kinkhabwala; John Reinus; Qiang Liu; Jennifer W Chuy
Journal:  J Gastrointest Oncol       Date:  2017-12
View more
  1 in total

1.  Relationship between hepatocellular carcinoma and depression via online database analysis.

Authors:  Tiantian Han; Yingchun Zhou; Danhua Li
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.